Bal Pharma Limited has informed the Exchange regarding Notice of Postal Ballot
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bal Pharma Limited has issued a Postal Ballot Notice to seek shareholder approval for the appointment of Dr. Mukesh Beekamchand (DIN: 11295580) as a Non-Executive Independent Director for a 5-year term up to 6th February 2031. Dr. Beekamchand, an MBBS and MDRC qualified doctor with around 25 years of experience in oncology, diabetic care, and pharmaceutical R&D, was initially appointed as an Additional Director on 13th November 2025. He has also been inducted into the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee effective 29th November 2025. Voting will be conducted electronically through NSDL from 9th January 2026 to 7th February 2026, with results to be announced on or before 10th February 2026.
This is a routine governance action to formalize an independent director's appointment through shareholder approval, which is required for regulatory compliance. There is no material impact on shareholders or stock price; investors just need to vote via the NSDL e-voting platform within the stated window.